secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2024-01-12T23:59:59+00:00
Accession:  0001104659-24-003764
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis raises ~$161.7M in stock/warrant offering; funds operations into 2026
----------------------------------------------------------------------------

- Public offering of 3,168,275 shares of common at $35.50 and pre-funded warrants for 1,056,725 shares at $35.4999.
- Underwriters exercised option to purchase an additional 633,750 shares; total net proceeds ~$161.7M.
- Proceeds to fund Phase 3 studies for ulixacaltamide and clinical development of PRAX-628, PRAX-562, PRAX-222.
- Company believes net proceeds plus existing cash will fund operating expenses and capex into 2026.
- Closing expected January 16, 2024, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000110465924003764/0001104659-24-003764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000110465924003764/tm243213d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-003764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer